Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission:A Preliminary Report of a Retrospective Cohort Study  

作　　者：Jin-nong ZHANG Wen-jing WANG Bo PENG Wei PENG Yi-sheng ZHANG Ya-ling WANG Yan WAN Jiang CHANG Ling MAO Xiao-ping MIAO Ya-nan LI Yi-fan ZHOU Bo HU 

机构地区：[1]Department of Emergency Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China [2]Peng Consulting Group,Salt Lake City 84108,UT,USA [3]Salt Lake Regional Medical Center,Heart and Lung Institute of Utah,Salt Lake City 84108,UT,USA [4]School of Materials Science and Engineering,Huazhong University of Science and Technology,Wuhan 430074,China [5]Department of Neurology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China [6]Department of Epidemiology and Biostatistics,Key Laboratory for Environment and Health,School of Public Health,Huazhong University of Science and Technology,Wuhan 430030,China

出　　处：《Current Medical Science》2020年第3期480-485,共6页当代医学科学（英文）

摘　　要：The efficient transmission of severe acute respiratory syndrome-2 coronavirus(SARS-CoV-2)from patients to health care workers or family members has been a worrisome and prominent feature of the ongoing outbreak.On the basis of clinical practice and in-vitro studies,we postulated that post-exposure prophylaxis(PEP)using Arbidol is associated with decreased infection among individuals exposed to confirmed cases of COVID-19 infection.We conducted a retrospective cohort study on family members and health care workers who were exposed to patients confirmed to have SARS-CoV-2 infection by real-time RT-PCR and chest computed tomography(CT)from January 1 to January 16,2020.The last follow-up date was Feb.26,2020.The emergence of fever and/or respiratory symptoms after exposure to the primary case was collected.The correlations between post-exposure prophylaxis and infection in household contacts and health care workers were respectively analyzed.A total of 66 members in 27 families and 124 health care workers had evidence of close exposure to patients with confirmed COVID-19.The Cox regression based on the data of the family members and health care workers with Arbidol or not showed that Arbidol PEP was a protective factor against the development of COVID-19(HR 0.025,95%CI 0.003-0.209,P=0.0006 for family members and HR 0.056,95%CI 0.005-0.662,P=0.0221 for health care workers).Our findings suggest Arbidol could reduce the infection risk of the novel coronavirus in hospital and family settings.This treatment should be promoted for PEP use and should be the subject of further investigation.

关 键 词：ARBIDOL COVID-19 SARS-CoV-2 post-exposure prophylaxis 

分 类 号：R73[医药卫生—肿瘤]